Deeper Insights for New Discoveries
SonoVanta™ is a safe, near-infrared contrast agent platform engineered to transform Photoacoustic Imaging — enabling targeted deep-tissue imaging and sensing for pre-clinical research.
The Problem: Photoacoustic Imaging (PAI)
A non-invasive and cost-effective imaging modality used in many preclinical studies
Offers high contrast and high spatial resolution to provide anatomical and functional information
Limitations of Current Contrast Agents
Commercially available PAI contrast agents are limited by several critical issues:
Poor safety profile
Low photostability
Limited depth of imaging
Poor solubility
Limited targeting
Our Solution: SonoVanta™
Safe — ICG-based platform (ICG is FDA approved)
Versatile — size tunable to cross biological barriers
Robust, cost effective & scalable — self-assembly production process
Compatible with major commercial instruments
Strong photoacoustic signal (no fluorescence) and photostable
Sharp NIR absorption peak at 895 nm wavelength for deep imaging
Targeted to improve specificity and limit off-target effects
Who We Serve
Academic Researchers
Access a versatile, near-infrared contrast agent platform purpose-built for pre-clinical PAI studies in diagnostic imaging, therapeutic efficacy, and drug biodistribution.
Pharmaceutical Companies
Accelerate drug development pipelines with precise, deep-tissue imaging data powered by SonoVanta™ — enabling clearer biodistribution and efficacy insights.
Technology Partners
Collaborate with NanOptical Biomedical to integrate SonoVanta™ into next-generation imaging systems and expand the frontier of photoacoustic applications.